Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren Hodgson, J. Carl Barrett, Jane Robertson et al.|British Journal of Cancer|2018Cited by 233
Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance settingBrian Dougherty, J. Carl Barrett, Zhongwu Lai et al.|Oncotarget|2017Cited by 99
Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in <i>BRCA1</i> or <i>BRCA2</i> are biologically similar and sensitive to PARP inhibitionBrian Dougherty, J. Carl Barrett, Zhongwu Lai et al.|Cancer Research|2015Cited by 4
466 Next generation sequencing of BRCA1 and BRCA2 genes in ovarian tumors captures all germline mutations and expands the potential treatment group for the PARP inhibitor olaparibKirsten M. Timms, Jerry S. Lanchbury, Chris Neff et al.|European Journal of Cancer|2015Cited by 0